Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes

Huan Yang, Haichao Wang, Yaakov A Levine, Manoj K Gunasekaran, Yongjun Wang, Meghan Addorisio, Shu Zhu, Wei Li, Jianhua Li, Dominique P V de Kleijn, Peder S Olofsson, H Shaw Warren, Mingzhu He, Yousef Al-Abed, Jesse Roth, Daniel J Antoine, Sangeeta S Chavan, Ulf Andersson, Kevin J Tracey

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Secreted by activated cells or passively released by damaged cells, extracellular HMGB1 is a prototypical damage-associated molecular pattern (DAMP) inflammatory mediator. During the course of developing extracorporeal approaches to treating injury and infection, we inadvertently discovered that haptoglobin, the acute phase protein that binds extracellular hemoglobin and targets cellular uptake through CD163, also binds HMGB1. Haptoglobin-HMGB1 complexes elicit the production of antiinflammatory enzymes (heme oxygenase-1) and cytokines (e.g., IL-10) in WT but not in CD163-deficient macrophages. Genetic disruption of haptoglobin or CD163 expression significantly enhances mortality rates in standardized models of intra-abdominal sepsis in mice. Administration of haptoglobin to WT and to haptoglobin gene-deficient animals confers significant protection. These findings reveal a mechanism for haptoglobin modulation of the inflammatory action of HMGB1, with significant implications for developing experimental strategies targeting HMGB1-dependent inflammatory diseases.

Original languageEnglish
JournalJCI Insight
Issue number7
Early online date19 May 2016
Publication statusPublished - 14 Jun 2016

Keywords / Materials (for Non-textual outputs)

  • Journal Article


Dive into the research topics of 'Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes'. Together they form a unique fingerprint.

Cite this